Active, Not Recruiting
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
NCT04141644
- Conditions
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
- Locations
-
- Huntsman Cancer Institute Salt Lake City, Utah, United States